Boehringer Ingelheim's Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation

News
1
3 Likes
2

That sounds promising. I wonder how it achieves greater cognitive function. Interesting stuff

2 Likes
3

interesting… 151515511

1 Like
4

Great news!

This study investigated whether the glycine transporter-1 inhibitor BI 425809 improves cognition in patients with schizophrenia.

Sarcosine is also a glycine transport inhibitor. I couldn’t tell you of course if this one is more effective than sarcosine but it seems to be the same mechanism.

BI 425809 improved cognition after 12 weeks in patients with schizophrenia; doses of 10 mg and 25 mg showed the largest separation from placebo. If these encouraging results are confirmed in phase 3 trials, BI 425809 could provide an effective treatment for cognitive impairment associated with schizophrenia.

It doesn’t look like this was the one paired with cognitive training, BI is also running a trial with both together.

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30513-7/fulltext

1 Like